162 related articles for article (PubMed ID: 8117652)
1. Design and evaluation of a thrombin-activable plasminogen activator.
Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY
Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
Hagemeyer CE; Tomic I; Weirich U; Graeber J; Nordt T; Runge MS; Bode C; Peter K
J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
[TBL] [Abstract][Full Text] [Related]
3. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.
Runge MS; Quertermous T; Zavodny PJ; Love TW; Bode C; Freitag M; Shaw SY; Huang PL; Chou CC; Mullins D
Proc Natl Acad Sci U S A; 1991 Nov; 88(22):10337-41. PubMed ID: 1946453
[TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of a recombinant chimeric plasminogen activator consisting of a fibrin peptide and a low molecular mass single-chain urokinase.
Jiao J; Yu M; Ru B
Biochimie; 2001; 83(11-12):1049-55. PubMed ID: 11879733
[TBL] [Abstract][Full Text] [Related]
5. A chimeric streptokinase with unexpected fibrinolytic selectivity.
Goldstein J; Matsueda GR; Shaw SY
Thromb Haemost; 1996 Sep; 76(3):429-38. PubMed ID: 8883282
[TBL] [Abstract][Full Text] [Related]
6. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes.
Higazi AA; Bdeir K; Hiss E; Arad S; Kuo A; Barghouti I; Cines DB
Blood; 1998 Sep; 92(6):2075-83. PubMed ID: 9731065
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
8. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
[TBL] [Abstract][Full Text] [Related]
9. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
10. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
11. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
[TBL] [Abstract][Full Text] [Related]
12. Characterization of thrombin- and plasmin-resistant mutants of recombinant human single chain urokinase-type plasminogen activator.
Eguchi Y; Sakata Y; Matsuda M; Osada H; Numao N; Ohmori M; Kondo K
J Biochem; 1990 Jul; 108(1):72-9. PubMed ID: 2146258
[TBL] [Abstract][Full Text] [Related]
13. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
[TBL] [Abstract][Full Text] [Related]
14. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
[TBL] [Abstract][Full Text] [Related]
15. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
[TBL] [Abstract][Full Text] [Related]
16. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin.
Miyake T; Hibino Y; Kobayashi Y; Yokoyama M; Watabe K; Ohmori M
J Biochem; 1988 Oct; 104(4):643-7. PubMed ID: 2977134
[TBL] [Abstract][Full Text] [Related]
18. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
19. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
20. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
